by Peter Ciszewski | Jan 30, 2019
The FDA approved ibrutinib for use in combination with obinutuzumab for treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. This is the first nonchemotherapy regimen indicated for this patient population. Ibrutinib...
by Peter Ciszewski | Jan 28, 2019
Alexion announced positive top line results in the Phase 3 study of Ultomiris (ravulizumab-cwvz), the long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome (aHUS). In the initial...
by Peter Ciszewski | Jan 23, 2019
Excellent podcast on rare diseases. Rare disease affects 1 in 10 people and over 30 million people in the US. At times we feel like society defines us by the disease instead of who we are as a person. Join hosts and advocates Anne Bruns and Seth Rotberg as they...
by Peter Ciszewski | Jan 22, 2019
Ron Cooper, President and CEO of Albireo, provides and overview of Cholestatic liver diseases. Cholestasis is a chronic condition resulting from an impairment of the biliary system, that provokes a decrease or interruption of bile secretion from the liver to...
by Peter Ciszewski | Jan 21, 2019
Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders, affecting approximately 1 in 2,500 people in the United States. The disease is named for the three physicians who first identified it in 1886 – Jean-Martin...
